ReviewTrends in immunology2025
Common origins of autoimmune diseases and lymphoid malignancies.
Review in Trends in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Interactions between autoimmune disorders and lymphoid malignancies have long been recognized; for instance, with prominent autoimmune manifestations in B- and T-cell lymphomas and an increased risk of lymphoma development in individuals with autoimmune diseases. More recently, several lines of evidence have shown that these two disease types have shared origins, defined by common genetic lesions and pathogenic cell states. Recent work suggests that the safeguards that protect normal lymphocyte development and adaptive immunity against the development of autoimmune diseases and lymphoid malignancies are based on similar sensing mechanisms of pathological lymphocytes. Here, we propose that mechanisms of negative selection that are designed to eliminate autoreactive lymphocytes also operate in suppressing the development of lymphoid malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.